The HinduLean L·
Pfizer's prostate cancer drug combination gets U.S. FDA priority review
For the combination drug, Pfizer said the FDA had set a target decision date in the last quarter of 2026
Read at The Hindu →
Science · 2 sources covering this
Pfizer's prostate cancer drug combination gets U.S. FDA priority review
For the combination drug, Pfizer said the FDA had set a target decision date in the last quarter of 2026
Coverage spectrum
2 L · 0 C · 0 R
How 2 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://hindustansphere.com/embed/cluster/cc33222bd73925d9dbbbab6fc90a120af70e65c8" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Pfizer's prostate cancer drug combination gets U.S. FDA priority review"></iframe>
